Articles On ImpediMed (ASX:IPD)

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ACF)) - Acrow Formwork and Construction Services ((ABC)) - AdBri ((APT)) - Afterpay ((APA)) - APA Group ((AMI)) - Aurelia Metals ((AOF)) - Australian Unity Office Fund (...

Today, Thursday the 26th of August, we are happy to buy Lovisa (ASX:LOV), Zip Co Ltd (ASX:Z1P), Oil Search Ltd (ASX:OSH), Idp Education Ltd (ASX:IEL), Dalrymple Bay (ASX:DBI), Universal Store (ASX:UNI), Acrow Formwork (ASX:ACF), Wagners Hld...

The Impedimed Limited (ASX: IPD) share price is appreciating after the company released its full-year results for FY21. At the time of writing, shares in the healthcare company are trading for 13 cents each – up 4%. For context, the ASX Al...

The ASX 200 health stocks index (XHJ) rose by 0.60% this morning, compared to the broader index which climbed by 0.40% Biopharmaceutical company Dimerix (ASX:DXB) announced that it has commenced ACTION3, a Phase III study in patients with f...

IDT Australia (ASX:IDT) jumped more than 20% after announcing that it has formalised activities with the Australian Government to potentially assist with the production of a COVID-19 vaccine. There was recent media interest surrounding a mR...

Wall Street rose ahead of world centrals banks meeting this week All three US stock market indexes bounced back on Friday, ahead of this week’s Jackson Hole Economic Policy Symposium, a virtual meeting of world central banks leaders held be...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

ImpediMed (IPD), The A2 Milk Company (A2M), Unibail-Rodamco-Westfield (URW), Harvey Norman Holdings (HVN) & IDP Education (IEL).

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f...

The market is trading near day’s high at the close, after the Reserve Bank of Australia’s (RBA) maintained status quo in its latest policy announcement and upgraded the country’s GDP growth estimates. The benchmark index ASX 200 was up 35.5...

The Impedimed Limited (ASX: IPD) share price is bouncing this morning after the company announced positive progress in its SOZO technology for heart patients.  The Impedimed share price has been seesawing between the opening price of 12 ce...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

The Impedimed Limited (ASX: IPD) share price was off to a flying start this morning, up 13% at market open. The positive price movement came as the medical technology company announced it received Food and Drug Administration (FDA) clearan...

Wall Street bounces back All major indices in the US have bounced back, after falling the previous day. Both the Dow Jones and S&P 500 rose by 0.93%, while tech heavy NASDAQ also rose by 1.19%. It was a broad-based increase across all s...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The ASX he...

ImpediMed (ASX.IPD) has announced the publication of a peer-reviewed manuscript demonstrating the clinical utility of its SOZO device in monitoring heart failure patients.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The health...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week “Another s...

The Impedimed Ltd (ASX: IPD) share price shot higher this morning, up 5% in morning trade.  This came after the ASX medical technology company reported a significant uptick in the number of tests conducted with one of its leading medical d...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((3PL)) - 3P Learning ((ALD)) - Ampol ((AD8)) - Audinate Group ((BIN)) - Bingo Industries ((BSL)) - BlueScope Steel ((BKG)) - Booktopia Group ((CNU)) - Chorus ((CGC)) - Co...

The Impedimed Limited (ASX: IPD) share price will be closely watched by investors this morning. This comes after the medical technology company announced that it has concluded its long-running Prevent trial. At the closing bell yesterday,...

Summary ImpediMed Limited (ASX:IPD) has secured the Health Information Trust Alliance Certification (HITRUST). HITRUST sets the global standard for safeguarding information. ImpediMed’s goal is to make continuous improvements in safeg...

Summary ImpediMed Limited (ASX:IPD) is an emerging contemporary medical technology company that produces a family of FDA cleared and CE Marked medical devices. The Company uses bioimpedance spectroscopy (BIS) technologies to generate p...

Summary ImpediMed Limited (ASX:IPD) has recently announced the publication of meta-analysis. The meta-analysis demonstrates effectiveness of ImpediMed's BIS L-Dex® technology in reducing rates of long-term breast cancer-related lymphoe...

The Impedimed Limited (ASX: IPD) share price lifted this morning on positive results from a significant cancer screening study. The results show that its bio-impedance spectroscopy (BIS) technology is more effective in screening and detect...

Summary ImpediMed Limited (ASX:IPD) has announced the first order for its SOZO® Digital Health Platform. Phoenix Healthcare Network has initially purchased five SOZO®® units, with implementation likely to commence in early FY21. SO...

“Program expansion with existing customers is a critical aspect of our growth strategy in the coming quarters”, says Richard Carreon, Managing Director and CEO of ImpediMed Limited. In a significant partnership update with NSW Health, ...

World leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies, ImpediMed Limited (ASX:IPD) has met a major milestone. The globally renowned pharmaceutical company, AstraZeneca has selec...

The Impedimed Limited (ASX: IPD) share price rocketed by 13.41% today to close the day’s trade at 9.3 cents per share. This came after the company announced that its Sozo medical device has been selected by AstraZeneca for use in a phase 2...

AstraZeneca has entered an agreement with Australian medical technology company ImpediMed under which it will use one of its digital health platforms for a clinical trial.

Medical technology company ImpediMed (ASX: IPD) unveiled a timely contract valued at over $2 million for its SOZO digital health platform, which paves the way for it to be used in a clinical trial by global biopharmaceutical giant AstraZene...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Earnings s...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With repor...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Scott Powe...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Victoria h...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Markets be...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks and of those which were trading on Tuesday, 66 were in positive territory over the last fortnight, 18 were flat and 47 saw t...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Participating in small cap raises is proving lucrative for investors, with shares in 47 small caps that tapped equity markets in April currently trading higher than the price at which they raised cash. Stockhead counted at least 66 offers i...

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve keen keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   This week’s big themes The ca...

It’s still a relatively difficult market to raise capital in, particularly at the junior end, but there are some that have convinced investors to part with their hard earned cash. We run through just which small and micro caps successfully...

The announcement lands just before markets open, ‘the TGA has approved our device’; the buy orders begin to pile up and the pre-open share price begins to surge. But while a nod from Australia’s drug and device regulator, the Therapeutic Go...